Research map: Metabolic and Glycemic Effects of Orforglipron, a GLP ‐1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta‐Analysis of Randomised Clinical Trials

Back to the article

Papers in this map

  1. RoB 2: a revised tool for assessing risk of bias in randomised trials · Jonathan A C Sterne · 2019 · 33351 citations · Cited by this paper
  2. Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era · 2026 · Related
  3. Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies · Julian P. T. Higgins · 2012 · 2168 citations · Cited by this paper
  4. An Evaluation of Longitudinal Thyroid Hormone Levels Over the Years Before and After Patients Started on Levothyroxine · 2026 · Related
  5. CINeMA: An approach for assessing confidence in the results of a network meta-analysis · Adriani Nikolakopoulou · 2020 · 1919 citations · Cited by this paper
  6. The Effect of Integrated Lifestyle Intervention Incorporating Calorie‐Carbohydrate Restriction With or Without Time‐Restricted Feeding for Remission of Type 2 Diabetes ( DIREM ): A Single Blind Randomised Controlled Trial · 2026 · Related
  7. Insulin Resistance: From Mechanisms to Therapeutic Strategies · Shin-Hae Lee · 2021 · 1095 citations · Cited by this paper
  8. Frequency of Insulin Resistance in Overweight Patients With Metabolic‐Associated Fatty Liver Disease ( MAFLD ) at a Tertiary Healthcare Centre in Bangladesh · 2026 · Related
  9. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery · Dan Eisenberg · 2022 · 963 citations · Cited by this paper
  10. Self‐Efficacy, Self‐Care, Glycaemic Control, and Quality of Life Among Adults With Type 2 Diabetes: A Scoping Review · 2026 · Related
  11. Network meta‐analysis, electrical networks and graph theory · Gerta Rücker · 2012 · 748 citations · Cited by this paper
  12. Efficacy of Metformin in Prevention of Glucocorticoid‐Induced Hyperglycemia in Patients Without Diabetes: A Meta‐Analysis · 2026 · Related
  13. netmeta : An R Package for Network Meta-Analysis Using Frequentist Methods · Sara Balduzzi · 2023 · 508 citations · Cited by this paper
  14. A Clinically Aligned Two‐Stage Machine Learning Framework for Predicting Hungry Bone Syndrome After Parathyroidectomy · 2026 · Related
  15. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity · Sean Wharton · 2023 · 464 citations · Cited by this paper
  16. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials · 2026 · Related
  17. A design‐by‐treatment interaction model for network meta‐analysis with random inconsistency effects · Dan Jackson · 2014 · 312 citations · Cited by this paper
  18. Predicting Diabetic Foot Ulcer Outcomes: Machine Learning‐Based Refinement of IWGDF ‐Approved Classifications for Outpatient Services · 2026 · Related
  19. Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions · Sirwan Khalid Ahmed · 2025 · 304 citations · Cited by this paper
  20. Semaglutide for the treatment of obesity · Ariana M. Chao · 2021 · 222 citations · Cited by this paper
  21. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · Sean Wharton · 2025 · 160 citations · Cited by this paper
  22. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials · Bo Åhrén · 2018 · 157 citations · Cited by this paper
  23. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions · Areesha Moiz · 2025 · 139 citations · Cited by this paper
  24. Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society · Dariush Mozaffarian · 2025 · 125 citations · Cited by this paper
  25. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes · Julio Rosenstock · 2025 · 115 citations · Cited by this paper
  26. Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants · Edward John Pratt · 2023 · 57 citations · Cited by this paper
  27. Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes · Edward John Pratt · 2023 · 56 citations · Cited by this paper
  28. Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review · Muhammad Y. Sheikh · 2025 · 44 citations · Cited by this paper
  29. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies · Ildiko Lingvay · 2022 · 36 citations · Cited by this paper
  30. Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies · Mohammad Iftekhar Ullah · 2025 · 36 citations · Cited by this paper
  31. Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges · Lihua Wang · 2025 · 30 citations · Cited by this paper
  32. Obesity Duration and Cardiometabolic Disease · Sharnendra K. Sidhu · 2023 · 28 citations · Cited by this paper
  33. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach · John L. Sievenpiper · 2025 · 22 citations · Cited by this paper
  34. Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes · Sumaya N. Almohareb · 2024 · 21 citations · Cited by this paper
  35. A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans · Brian Finan · 2025 · 19 citations · Cited by this paper
  36. Liver and obesity: a narrative review · Amedeo Lonardo · 2025 · 18 citations · Cited by this paper
  37. The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses · Nazanin Zamanian · 2025 · 14 citations · Cited by this paper
  38. The site of waist measurement impacts the estimation of visceral fat: results from three-dimensional photonic body scanning · Katja Repp · 2021 · 6 citations · Cited by this paper
  39. Obesity care in Chinese adults: from evidence to clinical practice · Jing An · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)